Pediatric Clinics of North America - CIPERJ

CARE OF PATIENTS WITH VASCULAR ANOMALIES
353
management guidelines are lacking for these complicated patients, highlighting
the need for further research.
References
[1] Mulliken JB, Glowacki J. Hemangiomas and vascular malformations in infants and
children: a classification based on endothelial characteristics. Plast Reconstr Surg 1982;
69(3):412–22.
[2] Fishman SJ, Mulliken JB. Vascular anomalies. A primer for pediatricians. Pediatr Clin
North Am 1998;45(6):1455–77.
[3] Enjolras O, Mulliken JB. Vascular tumors and vascular malformations (new issues). Adv
Dermatol 1997;13:375–423.
[4] Drolet B, Esterly N, Frieden IJ. Hemangiomas in children. N Engl J Med 1999;341(3):
173–81.
[5] Haggstrom AN, Drolet BA, Baselga E, et al. Prospective study of infantile hemangiomas:
clinical characteristics predicting complications and treatment. Pediatrics 2006;118:882–7.
[6] Mulliken JB, Enjoras O. Congenital hemangiomas and infantile hemangioma: missing links.
J Am Acad Dermatol 2004;50(6):875–82.
[7] North PE, Waner M, Mizeracki A, et al. GLUT 1: a newly discovered immunohistochemical
marker for juvenile hemangiomas. Human Pathology 2000;31(1):11–22.
[8] Orlow SJ, Isakoff MS, Blei F. Increased risk of symptomatic hemangiomas of the airway in
association with cutaneous hemangiomas in a ‘‘beard’’ distribution. J Pediatr 1997;131:643–6.
[9] Stockman A, Boralevi F, Taieb A, et al. SACRAL syndrome: spinal dysraphism, anogenital,
cutaneous, renal and urologic anomalies, associated with an angioma of lumbosacral localization.
Dermatology 2007;214(1):40–5.
[10] Drolet B, Garzon M. SACRAL syndrome. Dermatology 2007;215(4):360–1.
[11] Isaacs H Jr. Fetal and neonatal hepatic tumors. J Pediatr Surg 2007;42(11):1789–803.
[12] Sari N, Yalcin B, Akuyuz C, et al. Infantile hepatic hemangioendothelioma with elevated
serum alpha-fetoprotein. Pediatr Hematol Oncol 2006;23(8):639–47.
[13] Christison-Lagay ER, Burrows PE, Alomari A, et al. Hepatic hemangiomas:subtype classification
and development of a clinical algorithm and registry. J Pediatr Surg 2007;42(1):62–7.
[14] Mehrabi A, Kashfi A, Fonauni H, et al. Primary malignant hepatic epithelioid hemangioendothelioma:
a comprehensive review of the literature with emphasis on the surgical therapy.
Cancer 2006;107(9):2108–21.
[15] Nord KM, Kandel J, Lefkowitch JH, et al. Mulitple cutaneous infantile hemangiomas
associated with hepatic angiosarcoma: case report and review of the literature. Pediatrics
2006;118(3):907–13.
[16] Lu M, Greer ML. Hypervascular multifocal hepatoblastoma:dynamic gadoliniumenhanced
MRI findings indistinguishable from infantile hemangioendothelioma. Pedriatr
Radiol 2007;37(6):587–91.
[17] Huang SA, Tu HM, Harney JW, et al. Severe hypothyroidism caused by type 3 iodothyronine
deiodinase in infantile hemangiomas. N Engl J Med 2000;343(3):185–9.
[18] Kalpatthi R, Germak J, Mizelle K, et al. Thyroid abnormalities in infantile hepatic hemangioendothelioma.
Pediatr Blood Cancer 2007;49(7):1021–4.
[19] Bronzetti G, Giardini A, Patrizi A, et al. Ipsilateral hemangioma and aortic arch anomalies
in posterior fossa malformations, hemangiomas, arterial anomalies, coarctation of the aorta,
and cardiac defects and eye abnormalities (PHACE) anomaly: report and review. Pediatrics
2004;113:412–5.
[20] Metry DW, Dowd CF, Barkovich AJ, et al. The many faces of PHACE syndrome. J Pediatr
2001;139:117–23.
[21] Metry DW, Haggstrom AN, Drolet BA, et al. A prospective study of PHACE syndrome in
infantile hemangiomas: demographic features, clinical findings, and complications. Am J
Med Genet A 2006;140:975–86.